Ubu

Ubu is a biotechnology company focused on advancing the field of targeted protein degradation (TPD) through its proprietary Ubu-ligase platform. The company develops a new class of medicines designed to harness the body's natural protein disposal mechanisms to eliminate disease-causing proteins that are otherwise considered undruggable. By utilizing a diverse set of small, potent, and modular E3 ligases, Ubu aims to overcome the limitations of current TPD technologies, which are largely restricted to a few ligases like Cereblon and VHL. This approach potentially allows for greater tissue specificity, reduced off-target effects, and expanded therapeutic applications across oncology and other complex diseases. Headquartered in Cambridge, Massachusetts, Ubu is led by experienced biotech entrepreneurs and scientists dedicated to transforming patient care through innovative protein degradation strategies.